Promotion and acceleration of diabetic ulcer healing by arginine-glycine-aspartic acid (RGD) peptide matrix. RGD...

Area of Science:

• Wound healing research
• Diabetic complications
• Biomaterials in medicine

Background:

• Diabetic foot ulcers represent a significant clinical challenge with high morbidity.
• Current treatments for chronic diabetic foot ulcers have limited efficacy.
• Novel therapeutic strategies are needed to accelerate wound closure.

Purpose of the Study:

• To evaluate the efficacy and safety of arginine-glycine-aspartic acid (RGD) peptide matrix for treating diabetic foot ulcers.
• To compare RGD peptide matrix treatment with placebo in a randomized controlled trial.

Main Methods:

• A prospective, multicenter, randomized, placebo-controlled, double-blind study.
• Sixty-five patients with chronic full-thickness neurotrophic diabetic foot ulcers were enrolled.
• Topical application of RGD peptide matrix or placebo twice weekly for up to 10 weeks.

Main Results:

• Complete ulcer healing occurred in 35% of patients treated with RGD peptide matrix versus 8% in the placebo group (P=0.02).
• Over 50% ulcer closure was achieved by 75% of RGD peptide matrix patients compared to 48% of placebo patients (P=0.03).
• RGD peptide matrix significantly accelerated the rate of ulcer closure over 10 weeks (P=0.03).

Conclusions:

• RGD peptide matrix treatment significantly promotes and accelerates the healing of chronic diabetic foot ulcers.
• The findings support the use of RGD peptide matrix as an effective therapeutic option for diabetic foot ulcers.